CAJ | 학술논문

目的探讨单纯125I放射性粒子植入治疗早期前列腺癌的临床疗效. 方法 2007年1月至2011年7月前列腺癌患者18例,年龄60 ～ 81岁,平均74岁.术前PSA 0.38 ～ 8.73 μg/L,平均5.09 μg/L.均经前列腺穿刺病理诊断为前列腺癌,Gleason评分5～6分,临床分期T1c～T2a.采用直肠B超引导下经会阴植入125I粒子治疗. 结果本组手术顺利,手术时间37～52 min,平均植入粒子54粒,术后住院时间3～4d.随访时间3～57个月,平均15个月,1例失访.随访17例血PSA无进展生存率为100％ (17/17),7例随访超过18个月,血PSA水平长期低于0.20 μg/L,其中3例波动于0 ～0.08 μg/L,3例波动于0.02 ～0.12 μg/L,1例波动于0.12 ～ 0.20 μg/L.17例均未出现严重并发症. 结论单纯125I放射性粒子植入治疗早期前列腺癌安全、有效.
목적 탐토단순125I방사성입자식입치료조기전렬선암적림상료효. 방법 2007년1월지2011년7월전렬선암환자18례,년령60 ～ 81세,평균74세.술전PSA 0.38 ～ 8.73 μg/L,평균5.09 μg/L.균경전렬선천자병리진단위전렬선암,Gleason평분5～6분,림상분기T1c～T2a.채용직장B초인도하경회음식입125I입자치료. 결과 본조수술순리,수술시간37～52 min,평균식입입자54립,술후주원시간3～4d.수방시간3～57개월,평균15개월,1례실방.수방17례혈PSA무진전생존솔위100％ (17/17),7례수방초과18개월,혈PSA수평장기저우0.20 μg/L,기중3례파동우0 ～0.08 μg/L,3례파동우0.02 ～0.12 μg/L,1례파동우0.12 ～ 0.20 μg/L.17례균미출현엄중병발증. 결론 단순125I방사성입자식입치료조기전렬선암안전、유효.
Objective To evaluate the clinical efficacy of permanent 125I prostate brachytherapy monotherapy in patients with early prostate cancer. Methods A total of 18 patients with prostate cancer was diagnosed by prostate biopsy,with Gleason score 5 - 6,average PSA 5.09 ng/ml (range,0.38 -8.73 ),and clinical stage T1c - T2a.All patients underwent 3-dimensional conformal brachytherapy with transperineal ultrasound-guide 125I seeds prostate implantation. Results None of the patients had any adverse events during the operation processes.The operation time was from 37 to 52 minutes and postoperative hospitalization time was from 3 to 4 days.The mean number of implanted 125I seeds was 54.All patients were followed up for 3 to 57 months with a mean of 15 months,while one patient was lost during followingup.The survival rate of PSA progression free was 100％ (17/17).The PSA was under 0.2 ng/ml for a long time in the 7 cases who had been followed-up for more than 18 months.The PSA did not show any rising trend in all 17 cases.No severe complications occurred in all cases. Conclusions Brachytherapy monotherapy with 125I seeds implantation is safe and effective for patients with early prostate cancer.